Telix Pharmaceuticals Limited

ASX:TLX Voorraadrapport

Marktkapitalisatie: AU$7.2b

Telix Pharmaceuticals Beheer

Beheer criteriumcontroles 4/4

Telix Pharmaceuticals' CEO is Chris Behrenbruch, appointed in Jul 2023, has a tenure of 1.33 years. total yearly compensation is A$1.02M, comprised of 49% salary and 51% bonuses, including company stock and options. directly owns 6.97% of the company’s shares, worth A$500.41M. The average tenure of the management team and the board of directors is 2.2 years and 7.2 years respectively.

Belangrijke informatie

Chris Behrenbruch

Algemeen directeur

AU$1.0m

Totale compensatie

Percentage CEO-salaris49.0%
Dienstverband CEO1.3yrs
Eigendom CEO7.0%
Management gemiddelde ambtstermijn2.2yrs
Gemiddelde ambtstermijn bestuur7.2yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Chris Behrenbruch's beloning veranderd ten opzichte van Telix Pharmaceuticals's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

AU$49m

Mar 31 2024n/an/a

AU$32m

Dec 31 2023AU$1mAU$499k

AU$5m

Sep 30 2023n/an/a

-AU$21m

Jun 30 2023n/an/a

-AU$48m

Mar 31 2023n/an/a

-AU$77m

Dec 31 2022AU$865kAU$422k

-AU$104m

Sep 30 2022n/an/a

-AU$111m

Jun 30 2022n/an/a

-AU$119m

Mar 31 2022n/an/a

-AU$100m

Dec 31 2021AU$620kAU$374k

-AU$81m

Sep 30 2021n/an/a

-AU$70m

Jun 30 2021n/an/a

-AU$59m

Mar 31 2021n/an/a

-AU$52m

Dec 31 2020AU$421kAU$295k

-AU$45m

Sep 30 2020n/an/a

-AU$40m

Jun 30 2020n/an/a

-AU$36m

Mar 31 2020n/an/a

-AU$32m

Dec 31 2019AU$460kAU$317k

-AU$28m

Sep 30 2019n/an/a

-AU$23m

Jun 30 2019n/an/a

-AU$19m

Mar 31 2019n/an/a

-AU$16m

Dec 31 2018AU$380kAU$280k

-AU$14m

Sep 30 2018n/an/a

-AU$12m

Jun 30 2018n/an/a

-AU$10m

Mar 31 2018n/an/a

-AU$8m

Dec 31 2017AU$303kAU$211k

-AU$6m

Compensatie versus markt: Chris's total compensation ($USD667.62K) is below average for companies of similar size in the Australian market ($USD2.23M).

Compensatie versus inkomsten: Chris's compensation has been consistent with company performance over the past year.


CEO

Chris Behrenbruch (48 yo)

1.3yrs

Tenure

AU$1,018,461

Compensatie

Dr. Christian P. Behrenbruch, also known as Chris, BEng (Hons), J.D., Ph.D. DPhil (Oxon), MBA (TRIUM), JD (Melb), FIEAust, GAICD, is Co-Founder, Chief Executive Officer and Managing Director of Telix Pharm...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Christian Behrenbruch
Co-Founder1.3yrsAU$1.02m6.97%
A$ 500.4m
Darren Smith
Group Chief Financial Officer2.3yrsAU$713.90k0.0019%
A$ 139.3k
Andreas Kluge
Chief Medical Advisorno dataAU$43.00k6.78%
A$ 486.4m
David Cade
Group Chief Medical Officerless than a yeargeen gegevens0.11%
A$ 8.0m
Richard Valeix
Chief Executive Officer of Telix Therapeutics3.5yrsAU$902.90k0.060%
A$ 4.3m
Darren Patti
Group Chief Operating Officerless than a yeargeen gegevens0.030%
A$ 2.1m
Michael Wheatcroft
Chief Scientist3.5yrsAU$167.76kgeen gegevens
Craig Ulrick
Chief Information Officer1.8yrsgeen gegevensgeen gegevens
Kyahn Williamson
Senior Vice President of Corporate Communications & Investor Relations3.3yrsgeen gegevensgeen gegevens
Lena Moran-Adams
Group General Counsel2.2yrsgeen gegevensgeen gegevens
Thomas Fromm
Vice President of Salesno datageen gegevensgeen gegevens
Meredith Crowe
Senior Vice President of Global People & Culture2.2yrsgeen gegevensgeen gegevens

2.2yrs

Gemiddelde duur

53.5yo

Gemiddelde leeftijd

Ervaren management: TLX's management team is considered experienced (2.2 years average tenure).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Christian Behrenbruch
Co-Founder7.8yrsAU$1.02m6.97%
A$ 500.4m
Harry McCann
Independent Non-Executive Chairman7.2yrsAU$188.28k0.34%
A$ 24.7m
Chaitanya Divgi
Member of the Scientific Advisory Boardno datageen gegevensgeen gegevens
Rodney Hicks
Member of the Scientific Advisory Boardno datageen gegevensgeen gegevens
Neil Bander
Member of the Scientific Advisory Boardno datageen gegevensgeen gegevens
Mark Nelson
Independent Non-Executive Director7.2yrsAU$103.30k1.08%
A$ 77.8m
Jann Skinner
Independent Non-Executive Director6.4yrsAU$111.56k0.18%
A$ 12.8m
Jean-François Chatal
Member of the Scientific Advisory Boardno datageen gegevensgeen gegevens
Jason Lewis
Member of the Scientific Advisory Boardno datageen gegevensgeen gegevens
Klaus Kopka
Member of the Scientific Advisory Boardno datageen gegevensgeen gegevens
Samuel Samnick
Member of the Scientific Advisory Boardno datageen gegevensgeen gegevens
Richard Baum
Member of the Scientific Advisory Boardno datageen gegevensgeen gegevens

7.2yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: TLX's board of directors are considered experienced (7.2 years average tenure).